600267 海正药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入7,874,541-9.50%10,373,07212,036,69012,136,46611,354,396
减:营业总成本7,323,585-9.75%10,134,42011,255,66611,492,42110,761,673
    其中:营业成本4,632,200-9.31%6,188,8216,998,6747,186,4676,441,030
               财务费用101,396-31.83%191,673262,748331,253412,503
               资产减值损失(186,768)123.19%(285,522)(126,037)(109,431)(75,337)
公允价值变动收益(13,227)-1,045.71%278(107,318)(17,769)731
投资收益181,056152.07%66,05625,06699,72834,437
    其中:对联营企业和合营企业的投资收益32,633-176.08%(60,373)(157,554)(75,745)(33,679)
营业利润606,425-0.86%89,443682,478700,070776,864
利润总额605,5207.48%(82,867)683,423644,191904,142
减:所得税费用95,235-9.46%14,148192,188133,560180,975
净利润510,28511.37%(97,015)491,234510,631723,167
减:非控股权益(5,028)-131.79%(3,844)2,37423,743305,973
股东净利润515,31316.49%(93,171)488,860486,888417,194

市场价值指针
每股收益 (元) *0.44015.79%-0.0800.4200.4300.430
每股派息 (元) *------0.1700.1400.050
每股净资产 (元) *6.8330.10%6.4256.3855.7486.917
审计意见 #--保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容